Business
R&D update: Mammalian Display service
R&D update: Mammalian Display service.
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n \n \n \n \n \n \n Fusion Antibodies plc\n \n \n \n (\"Fusion\" or the \"Company\")\n \n \n \n \n \n \n R&D update: Mammalian Display service\n \n \n \n \n New commerical service from\n \n \n OptiMAL® programme\n \n \n \n \n \n \n \n \n Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that is has launched a new commercial service from its R&D programme, named\n Mammalian Display, for high volume mammalian cell surface expression and screening of antibodies.\n \n \n \n \n \n Mammalian Display is the first service from the Company's ongoing OptiMAL® programme which Fusion has commercialised and is now offering to clients. The service is particularly suited to companies specialising in the identification of therapeutic antibodies from focussed libraries of sequences, such as would be required by those entities using artificial intelligence (\"AI\") or machine learning (\"ML\") which can require the expression and screening of small libraries of tens of thousands of antibodies.\n \n \n \n \n \n Fusion collaborates with its clients in every stage of pre-clinical antibody development, with decades of experience and unique proprietary platforms. A fully integrated end-to-end service from therapeutic target nomination and discovery through to stable cell line development in readiness for GMP production is also available. Initial market research that the Company has conducted with AI/ML experts has confirmed that there is a need for expression of focussed libraries of antibodies in the way delivered by the Mammalian Display service.\n \n \n \n \n \n The Company is continuing to work on other aspects of the OptiMAL® programme, and in particular the development of the fully human antibody library.\n \n \n \n \n \n \n Fusion Antibodies CEO, Adrian Kinkaid said\n \n : \"We are delighted to be able to announce the successful development of the Mammalian Display technology, an output from our OptiMAL\n ®\n \n research programme.\n \n \n As our industry rapidly turns to find new ways to hasten the development of better bio-therapeutics to the clinic, we also anticipate deploying these capabilities to bring AI generated antibody sequences out of wor...